Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431515 | 0.90 | ADORA1 (0.38) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL7665402 | 0.87 | ADORA2A (0.41) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5861525 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5860446 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5431586 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5861429 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5860233 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5861492 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5701832 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR | |
| SCHEMBL5428341 | 0.86 | ADORA2B (0.53) | ADORA1ADORA2AADORA2BADORA3MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1372661-B1 | GLYCOL DERIVATVES OF XANTHINES FOR TREATING IRRITABLE BOWEL SYNDROME | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | claimed |
| EP-0970081-B1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LTD (GB) | 2005-09-14 | — | — | EP | claimed |
| JP-2004523559-A | — | — | 2004-08-05 | — | — | JP | claimed |
| US-6770267-B2 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2004-08-03 | — | — | US | claimed |
| US-20040072848-A1 | Methods of treating irritable bowel syndrome and functional dyspepsia | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | claimed |
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | claimed |
| EP-1104422-B1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-02-18 | — | — | EP | claimed |
| EP-1372661-A2 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA | SmithKline Beecham Corporation (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | DALUGE SUSAN MARY (US) | 2003-09-25 | — | — | US | claimed |
| US-6608069-B1 | Treating AIDS-related diarrhea or infectious diarrhea, tissue damage or dermatitis associated with leukocyte infiltration into tissue, asthma, inflammatory bowel condition, eczema, or psoriasis | SMITHKLINE BEECHAM CORPORATION | 2003-08-19 | — | — | US | claimed |
| US-20030032804-A1 | Methods of treating periodontal disease | SMITHKLINE BEECHAM CORPORATION | 2003-02-13 | — | — | US | claimed |
| WO-2002067942-A2 | METHODS OF TREATING IRRITABLE BOWEL SYNDROME AND FUNCTIONAL DYSPEPSIA | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | claimed |
| US-6355646-B1 | IMMUNOLOGY TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS SEPTIC SHOCK | GLAXO WELLCOME INC. | 2002-03-12 | — | — | US | claimed |
| EP-1104422-A1 | PHENYL XANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-06-06 | — | — | EP | claimed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | claimed |
| US-20070082919-A1 | Process for Preparing a Co-Precipitate of a Non-Crystalline Solid Drug Substance | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-12 | — | — | US | disclosed |
| EP-1682093-A1 | PROCESS FOR PREPARING A CO-PRECIPITATE OF A NON-CRYSTALLINE SOLID DRUG SUBSTANCE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2000009507-A1 | PHENYL YANTHINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-02-24 | — | — | WO | disclosed |
| EP-0970081-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998035966-A1 | SUBSTITUTED (1,3-BIS(CYCLOHEXYLMETHYL)-1,2,3,6-TETRAHYDRO-2,6-DIOXO-9H-PURIN-8-YL)PHENYL DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF INFLAMMATORY CONDITIONS AND IMMUNE DISORDERS | GLAXO GROUP LIMITED (GB) | 1998-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082919-A1 | Process for Preparing a Co-Precipitate of a Non-Crystalline Solid Drug Substance | CNDP2, SIGMAR1, NONO | ADORA1 2815/4885ADORA2A 3447/4885ADORA2B 3065/4885 |
| US-20030181471-A1 | Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-YI)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders | NOD1, PURB, NOD2 | ADORA1 276/4885ADORA2A 996/4885ADORA2B 617/4885 |
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | ADORA1 1338/4885ADORA2A 660/4885ADORA2B 680/4885 |
| US-20040072848-A1 | Methods of treating irritable bowel syndrome and functional dyspepsia | SI, XDH, SLC10A2 | ADORA1 264/4885ADORA2A 175/4885ADORA2B 247/4885 |
| US-20030032804-A1 | Methods of treating periodontal disease | HPGDS, SELP, ALPI | ADORA1 531/4885ADORA2A 300/4885ADORA2B 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.